

TRADEMARK ASSIGNMENT

Electronic Version v1.1  
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	SECURITY INTEREST

CONVEYING PARTY DATA

Name	Formerly	Execution Date	Entity Type
Precision Therapeutics, Inc.		03/06/2012	CORPORATION: DELAWARE

RECEIVING PARTY DATA

Name:	Cowen Healthcare Royalty Partners II, L.P.
Street Address:	177 Broad Street, Suite 1101
City:	Stamford
State/Country:	CONNECTICUT
Postal Code:	06901
Entity Type:	LIMITED PARTNERSHIP: DELAWARE

PROPERTY NUMBERS Total: 13

Property Type	Number	Word Mark
Registration Number:	2339226	CHEMOFX
Serial Number:	76132424	RAYFX
Registration Number:	2190715	PRECISIONTHERAPEUTICS
Registration Number:	2499516	CHEMOFX ASSAY
Serial Number:	77805337	LUNGEXPRESS DX
Registration Number:	2739805	PRECISION THERAPEUTICS
Registration Number:	2736154	PRECISION THERAPEUTICS
Registration Number:	3724556	CHEMOFX
Registration Number:	3887693	CHEMOFX PRO
Serial Number:	77956397	GENOFX
Serial Number:	85202292	BIOSPECIFX
Serial Number:	85202518	PROFILEFX
Serial Number:	85336388	GENEFX

CORRESPONDENCE DATA

900217307

**TRADEMARK**  
 REEL: 004736 FRAME: 0373

CH \$340.00 2339226

Fax Number: (312)984-7700  
Phone: 312.372.2000  
Email: sschlessinger@mwe.com

*Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent via US Mail.*

Correspondent Name: Brett E. Bachtell  
Address Line 1: 227 W. Monroe Street, Suite 4400  
Address Line 2: McDermott Will & Emery LLP  
Address Line 4: Chicago, ILLINOIS 60606-5096

ATTORNEY DOCKET NUMBER:	77613-038 BEB/CMV
NAME OF SUBMITTER:	Brett E. Bachtell
Signature:	/Brett E. Bachtell/
Date:	03/14/2012

**Total Attachments: 12**

source=Precision Therapeutics to Cowen Healthcare Patent and Trademark Security Agreement#page1.tif  
source=Precision Therapeutics to Cowen Healthcare Patent and Trademark Security Agreement#page2.tif  
source=Precision Therapeutics to Cowen Healthcare Patent and Trademark Security Agreement#page3.tif  
source=Precision Therapeutics to Cowen Healthcare Patent and Trademark Security Agreement#page4.tif  
source=Precision Therapeutics to Cowen Healthcare Patent and Trademark Security Agreement#page5.tif  
source=Precision Therapeutics to Cowen Healthcare Patent and Trademark Security Agreement#page6.tif  
source=Precision Therapeutics to Cowen Healthcare Patent and Trademark Security Agreement#page7.tif  
source=Precision Therapeutics to Cowen Healthcare Patent and Trademark Security Agreement#page8.tif  
source=Precision Therapeutics to Cowen Healthcare Patent and Trademark Security Agreement#page9.tif  
source=Precision Therapeutics to Cowen Healthcare Patent and Trademark Security Agreement#page10.tif  
source=Precision Therapeutics to Cowen Healthcare Patent and Trademark Security Agreement#page11.tif  
source=Precision Therapeutics to Cowen Healthcare Patent and Trademark Security Agreement#page12.tif

## PATENT AND TRADEMARK SECURITY AGREEMENT

THIS PATENT AND TRADEMARK SECURITY AGREEMENT (as amended, supplemented or otherwise modified from time to time, this "Agreement") is made and entered into as of March 6, 2012, by and between PRECISION THERAPEUTICS, INC., a Delaware corporation ("Borrower"), and each Subsidiary of Borrower that becomes a party hereto by joinder (collectively, the "Guarantors" and, together with Borrower, the "Grantors"), and COWEN HEALTHCARE ROYALTY PARTNERS II, L.P., a Delaware limited partnership, as lender (the "Lender").

### RECITALS:

A. Borrower and Lender are parties to that certain Loan Agreement dated as of March 6, 2012 (as amended, supplemented or otherwise modified from time to time, and as refunded or refinanced, whether in whole or in part, the "Loan Agreement").

B. As a condition precedent to the Lender's obligations under the Loan Agreement, Borrower has entered into that certain Security Agreement dated as of even date hereof (as may be amended, supplemented or otherwise modified from time to time, the "Security Agreement") with the Lender, pursuant to which Borrower is required to execute and deliver this Agreement to the Lender.

C. Pursuant to the terms of the Security Agreement, Borrower has granted to the Lender, as general and continuing security for the due performance and payment of all of the Secured Obligations, a first-ranking (subject only to any Liens permitted under Sections 9.03(b), 9.03(c), 9.03(d), 9.03(g) (to the extent provided in any control agreement), and 9.03(i) (to the extent provided in any intercreditor agreement) of the Loan Agreement) security interest in and to the Collateral, including all right, title and interest of Borrower in, to and under all now owned and hereafter acquired patents, patent applications, patent licenses, trademarks, trademark applications and trademark licenses, and all products and proceeds thereof.

D. From time to time after the date hereof, pursuant to Section 8.13 of the Loan Agreement, Subsidiaries of Borrower may be required to execute joinder agreements or guarantees with respect to Borrower's obligations under the Loan Documents and, in connection therewith, become parties hereto.

NOW, THEREFORE, in consideration of the premises set forth herein and for other good and valuable consideration, receipt and sufficiency of which are hereby acknowledged, each Grantor agrees as follows:

1. Incorporation of the Security Agreement. The Security Agreement and the terms and provisions thereof are hereby incorporated herein in their entirety by this reference thereto. All terms capitalized but not otherwise defined herein shall have the same meanings herein as in the Security Agreement.

2. Grant and Reaffirmation of Grant of Security Interests. To secure the due performance and payment of all of the Secured Obligations, each Grantor hereby grants to the

Lender, a continuing first-ranking (subject only to any Liens permitted under Sections 9.03(b), 9.03(c), 9.03(d), 9.03(g) (to the extent provided in any control agreement), and 9.03(i) (to the extent provided in any intercreditor agreement) of the Loan Agreement) security interest in such Grantor's entire right, title and interest in and to the following, whether now owned or existing or hereafter created, acquired or arising (for the avoidance of doubt, excluding, in each case, any items that are Excluded Property pursuant to the terms and conditions of the Security Agreement):

(i) each trademark and trademark application owned by such Grantor, including, without limitation, each trademark and trademark application referred to in Schedule 1 annexed hereto, together with any reissues, continuations or extensions thereof and all goodwill associated therewith;

(ii) each trademark license to which such Grantor is a party, together with all goodwill associated therewith;

(iii) all products and proceeds of the foregoing, including, without limitation, any claim by such Grantor against third parties for past, present or future infringement of any such trademark, including, without limitation, any trademark referred to in Schedule 1 annexed hereto (as such Schedule may be supplemented for Grantors which become parties hereto after the date hereof), any trademark issued pursuant to a trademark application referred to in Schedule 1 (as such Schedule may be supplemented for Grantors which become parties hereto after the date hereof) and any trademark licensed under any trademark license;

(iv) each patent and patent application owned by such Grantor, including, without limitation, each patent and patent application referred to in Schedule 2 annexed hereto (as such Schedule may be supplemented for Grantors which become parties hereto after the date hereof), together with any reissues, continuations or extensions thereof and all goodwill associated therewith;

(v) each patent license to which such Grantor is a party, together with all goodwill associated therewith; and

(vi) all products and proceeds of the foregoing, including, without limitation, any claim by such Grantor against third parties for past, present or future infringement of any such patent, including, without limitation, any patent referred to in Schedule 2 annexed hereto (as such Schedule may be supplemented for Grantors which become parties hereto after the date hereof), any patent issued pursuant to a patent application referred to in Schedule 2 (as such Schedule may be supplemented for Grantors which become parties hereto after the date hereof) and any patent licensed under any patent license.


3. Recordation with the United States Patent and Trademark Office. The Lender may from time to time, and without any further action by any Grantor, make such filings as are necessary or advisable to record or otherwise perfect its security interest in the collateral described under Section 2 of this Agreement with the United States Patent and Trademark Office.

[SIGNATURE PAGE FOLLOWS]

- 2 -

**IN WITNESS WHEREOF**, the parties hereto have caused this Agreement to be duly executed by their respective authorized officers as of the date first above written.

**PRECISION THERAPEUTICS, INC.**

By:   
Name: \_\_\_\_\_  
Title: Dawn F. Kypole  
          cfo

**COWEN HEALTHCARE ROYALTY PARTNERS  
II, L.P.**

By: Cowen Healthcare Royalty GP II, LLC,  
      its General Partner

By: \_\_\_\_\_  
Name:  
Title:


**IN WITNESS WHEREOF**, the parties hereto have caused this Agreement to be duly executed by their respective authorized officers as of the date first above written.

**PRECISION THERAPEUTICS, INC.**

By: \_\_\_\_\_  
Name:  
Title:

**COWEN HEALTHCARE ROYALTY PARTNERS  
II, L.P.**

By: Cowen Healthcare Royalty GP II, LLC,  
its General Partner

By:  \_\_\_\_\_  
Name: Todd C. Davis  
Title: Managing Director

**SCHEDULE 1**

**TRADEMARKS AND TRADEMARK APPLICATIONS**

<b>Mark</b>	<b>Reg. No (Serial No)</b>	<b>Reg. Date (Filing Date)</b>	<b>Record Owner/Liens/Comments</b>
CHEMOFX	2339226	04/04/00	Certificate of Merger between Precision Therapeutics, Inc. (PA) and Precision Therapeutics, Inc. (DE) recorded on 07/02/01
RAYFX	(76132424)	(09/20/00)	Certificate of Merger between Precision Therapeutics, Inc. (PA) and Precision Therapeutics, Inc. (DE) recorded on 07/02/01
PRECISION THERAPEUTICS	2190715	(09/22/98)	Certificate of Merger between Precision Therapeutics, Inc. (PA) and Precision Therapeutics, Inc. (DE) recorded on 07/02/01
CHEMOFX ASSAY	2499516	10/23/01	Certificate of Merger between Precision Therapeutics, Inc. (PA) and Precision Therapeutics, Inc. (DE) recorded on 07/02/01
LUNGEXPRESS DX	(77805337)	(08/14/09)	Med Biogene Inc. assigned security interest to Precision Therapeutics, Inc. (DE) on 05/04/11
PRECISION THERAPEUTICS	2739805	07/22/03	Precision Therapeutics, Inc.
PRECISION THERAPEUTICS	2736154	07/15/03	Precision Therapeutics, Inc.
CHEMOFX	3724556	12/15/09	Precision Therapeutics, Inc.
CHEMOFX PRO	3887693	12/07/10	Precision Therapeutics, Inc.
GENOFX	(77956397)	(03/11/10)	Precision Therapeutics, Inc.
BIOSPECIFX	(85202292)	(12/20/10)	Precision Therapeutics, Inc.
PROFILEFX	(85202518)	(12/21/10)	Precision Therapeutics, Inc.
GENEFX	(85336388)	(06/02/11)	Precision Therapeutics, Inc.

## SCHEDULE 2

### PATENTS AND PATENT APPLICATIONS

Title	Application No.	Application Date	Registration No.	Case Status	Country	Expiry Date
PRECISE EFFICACY ASSAY METHODS FOR ACTIVE AGENTS INCLUDING CHEMOTHERAPEUTIC AGENTS	36493/97	Jul-10-1997	712302	Registered	Australia	Jul-10-2017
METHOD FOR PREPARING A BIOPSY SAMPLE OF TISSUE CONTAINING MALIGNANT CELLS FOR CHEMOSENSITIVITY TESTING	PI9710348-9	Jul-10-1997		Abandoned	Brazil	
PRECISE EFFICACY ASSAY METHODS FOR ACTIVE AGENTS INCLUDING CHEMOTHERAPEUTIC AGENTS	2,259,984	Jul-10-1997	2,259,984	Registered	Canada	Jul-10-2017
PRECISE EFFICACY ASSAY METHODS FOR ACTIVE AGENTS INCLUDING CHEMOTHERAPEUTIC AGENTS	97933267.3	Jul-10-1997	0912085	Registered	Switzerland	Jul-10-2017
PRECISE EFFICACY ASSAY METHODS FOR ACTIVE AGENTS INCLUDING CHEMOTHERAPEUTIC AGENTS	97196143.3	Jul-10-1997	97196143.3	Registered	China	Jul-10-2017
PRECISE EFFICACY ASSAY METHODS FOR ACTIVE AGENTS INCLUDING CHEMOTHERAPEUTIC AGENTS	97933267.3	Jul-10-1997	0912085	Registered	Germany	Jul-10-2017
PRECISE EFFICACY ASSAY METHODS FOR ACTIVE AGENTS INCLUDING CHEMOTHERAPEUTIC AGENTS	97933267.3	Jul-10-1997	0912085	EP Granted	European Patent Office	Jul-10-2017
PRECISE EFFICACY ASSAY METHODS FOR ACTIVE AGENTS INCLUDING CHEMOTHERAPEUTIC AGENTS	97933267.3	Jul-10-1997	0912085	Registered	Spain	Jul-10-2017
PRECISE EFFICACY ASSAY METHODS FOR ACTIVE AGENTS INCLUDING CHEMOTHERAPEUTIC AGENTS	97933267.3	Jul-10-1997	0912085	Registered	France	Jul-10-2017
PRECISE EFFICACY ASSAY METHODS FOR ACTIVE AGENTS INCLUDING CHEMOTHERAPEUTIC AGENTS	97933267.3	Jul-10-1997	0912085	Registered	United Kingdom	Jul-10-2017
PRECISE EFFICACY ASSAY METHODS FOR ACTIVE AGENTS INCLUDING CHEMOTHERAPEUTIC AGENTS	127964	Jul-10-1997	127694	Registered	Israel	Jul-10-2017
PRECISE EFFICACY ASSAY METHODS FOR ACTIVE AGENTS INCLUDING CHEMOTHERAPEUTIC AGENTS	97933267.3	Jul-10-1997	0912085	Registered	Italy	Jul-10-2017
PRECISE EFFICACY ASSAY METHODS FOR ACTIVE AGENTS INCLUDING CHEMOTHERAPEUTIC AGENTS	10-506069	Jul-10-1997	4108128	Registered	Japan	Jul-10-2017
PRECISE EFFICACY ASSAY METHODS FOR ACTIVE AGENTS INCLUDING CHEMOTHERAPEUTIC AGENTS	333830	Jul-10-1997	333830	Abandoned	New Zealand	



Title	Application No.	Application Date	Registration No.	Case Status	Country	Expiry Date
METHOD FOR PREPARING CELL CULTURES FROM BIOLOGICAL SPECIMENS FOR CHEMOTHERAPEUTIC AND OTHER ASSAYS	08/679,056	Jul-12-1996	5,728,541	Registered	United States of America	Jul-12-2016
PRECISE EFFICACY ASSAY METHODS FOR ACTIVE AGENTS INCLUDING CHEMOTHERAPEUTIC AGENTS	PCT/US97/11595	Jul-10-1997		Expired/PCT Period Over	Patent Cooperation Treaty	
PRECISE EFFICACY ASSAY METHODS FOR ACTIVE AGENTS INCLUDING CHEMOTHERAPEUTIC AGENTS	09/040,161	Mar-17-1998	6,900,027	Registered	United States of America	Jul-12-2016
METHOD FOR PREPARING CELL CULTURES FROM BIOLOGICAL SPECIMENS FOR CHEMOTHERAPEUTIC AND OTHER ASSAYS	10/205,887	Jul-26-2002	6,887,680	Registered	United States of America	Jul-12-2016
METHOD FOR SELECTING THERAPEUTIC AGENTS FOR CANCER	11/081,827	Jul-26-2002	7,314,731	Registered	United States of America	Jul-12-2016
METHODS FOR DETERMINING EFFICACY OF CHEMOTHERAPEUTIC AGENTS FOR A PATIENT PRIOR TO TREATMENT	11/944,884	Nov-26-2007	7,501,260	Registered	United States of America	Jul-12-2016
METHODS FOR DETERMINING EFFICACY OF CHEMOTHERAPEUTIC AGENTS	12/244,463	Oct-02-2008	7,771,963	Registered	United States of America	Jul-12-2016
METHODS FOR DETERMINING EFFICACY OF CHEMOTHERAPEUTIC AGENTS	12/828,665	Jul-01-2010	8,058,025	Registered	United States of America	Jul-12-2016
METHODS FOR DETERMINING EFFICACY OF CHEMOTHERAPEUTIC AGENTS	13/267,581	Oct-06-2011		Pending	United States of America	
METHOD FOR CULTURING AND ASSAYING CELLS	09/039,957	Mar-16-1998	6,933,129	Registered	United States of America	Jul-12-2016
METHOD OF PREPARING CELL CULTURES FROM BIOLOGICAL SPECIMENS FOR ASSAYING A RESPONSE TO AN AGENT	11/073,931	Mar-08-2005	7,112,415	Registered	United States of America	Jul-12-2016
METHOD FOR PREPARING CELL CULTURES FROM BIOLOGICAL SPECIMENS FOR ASSAYING SECRETED FACTORS	11/504,098	Aug-15-2006	7,563,593	Registered	United States of America	Oct-12-2016
METHOD FOR SELECTING THERAPEUTIC AGENTS FOR CANCER TREATMENT	12/208,076	Sep-10-2008	7,678,552	Registered	United States of America	Jul-12-2016
ASSAYING CELLULAR MARKER FOR THE EVALUATION OF TUMORS	12/690,529	Jan-20-2010		Allowed	United States of America	
STAINING AGENTS AND PROTOCOLS FOR CHARACTERIZING MALIGNANT CELLS IN CULTURE	09/095,993	Jun-11-1998		Abandoned	United States of America	
METHOD FOR USING MULTICELLULAR PARTICULATES TO ANALYZE MALIGNANT OR HYPERPROLIFERATIVE TISSUE	09/189,310	Nov-10-1998	6,416,967	Registered	United States of America	Jul-12-2016

Title	Application No.	Application Date	Registration No.	Case Status	Country	Expiry Date
METHOD FOR THE GENETIC ANALYSIS OF PROLIFERATING CELLS	09/691,492	Oct-18-2000		Abandoned	United States of America	
METHOD FOR THE GENETIC ANALYSIS OF PROLIFERATING CELLS	PCT/US01/32540	Oct-18-2001		Expired/PCT Period Over	Patent Cooperation Treaty	
METHOD FOR TANDEM GENOMIC/PROTEOMIC ANALYSES OF PROLIFERATING CELLS	10/399,563	Oct-18-2001		Abandoned	United States of America	
METHOD FOR PREPARING CELL CULTURES FROM BIOLOGICAL SPECIMENS FOR CHEMOTHERAPEUTIC AND OTHER ASSAYS	03784853.8	Jul-30-2003	60334025.3	Registered	Germany	Jul-30-2023
METHOD FOR PREPARING CELL CULTURES FROM BIOLOGICAL SPECIMENS FOR CHEMOTHERAPEUTIC AND OTHER ASSAYS	03784853.8	Jul-30-2003	1572969	Registered	European Patent Office	Jul-30-2023
METHOD FOR PREPARING CELL CULTURES FROM BIOLOGICAL SPECIMENS FOR CHEMOTHERAPEUTIC AND OTHER ASSAYS	03784853.8	Jul-30-2003	1572969	Registered	France	Jul-30-2023
METHOD FOR PREPARING CELL CULTURES FROM BIOLOGICAL SPECIMENS FOR CHEMOTHERAPEUTIC AND OTHER ASSAYS	03784853.8	Jul-30-2003	1572969	Registered	United Kingdom	Jul-30-2023
METHOD FOR PREPARING CELL CULTURES FROM BIOLOGICAL SPECIMENS FOR CHEMOTHERAPEUTIC AND OTHER ASSAYS	10/208,480	Jul-30-2002		Abandoned	United States of America	
METHOD FOR PREPARING CELL CULTURES FROM BIOLOGICAL SPECIMENS FOR CHEMOTHERAPEUTIC AND OTHER ASSAYS	PCT/US2003/023888	Jul-30-2003		Expired/PCT Period Over	Patent Cooperation Treaty	
METHOD FOR PREPARING CELL CULTURES FROM BIOLOGICAL SPECIMENS FOR CHEMOTHERAPEUTIC AND OTHER ASSAYS	11/595,967	Nov-13-2006	7,972,769	Registered	United States of America	Jun-16-2024
METHODS FOR ASSESSING EFFICACY OF CHEMOTHERAPEUTIC AGENTS	03779093.8	Oct-10-2003	1556515	Registered	Germany	Oct-10-2023
METHODS FOR ASSESSING EFFICACY OF CHEMOTHERAPEUTIC AGENTS	03779093.8	Oct-10-2003	1556515	Registered	European Patent Office	Oct-10-2023
METHODS FOR ASSESSING EFFICACY OF CHEMOTHERAPEUTIC AGENTS	03779093.8	Oct-10-2003	1556515	Registered	France	Oct-10-2023
METHODS FOR ASSESSING EFFICACY OF CHEMOTHERAPEUTIC AGENTS	03779093.8	Oct-10-2003	1556515	Registered	United Kingdom	Oct-10-2023
METHODS FOR ASSESSING EFFICACY OF CHEMOTHERAPEUTIC AGENTS	60/417,439	Oct-10-2002		Expired	United States of America	
METHODS FOR ASSESSING EFFICACY OF CHEMOTHERAPEUTIC AGENTS	PCT/US03/32285	Oct-10-2003		Expired/PCT Period Over	Patent Cooperation Treaty	

Title	Application No.	Application Date	Registration No.	Case Status	Country	Expiry Date
METHODS FOR ASSESSING EFFICACY OF CHEMOTHERAPEUTIC AGENTS	10/336,659	Jan-02-2003		Abandoned	United States of America	
METHODS FOR ASSESSING EFFICACY OF CHEMOTHERAPEUTIC AGENTS	11/713,662	Mar-05-2007	7,575,868	Registered	United States of America	Jan-02-2023
METHODS FOR ASSESSING EFFICACY OF CHEMOTHERAPEUTIC AGENTS	12/510,671	Jul-28-2009	7,829,288	Registered	United States of America	Jan-02-2023
METHODS FOR ASSESSING EFFICACY OF CHEMOTHERAPEUTIC AGENTS	12/898,232	Oct-05-2010	8,039,213	Registered	United States of America	Jan-02-2023
METHODS FOR ASSESSING EFFICACY OF CHEMOTHERAPEUTIC AGENTS	13/247,436	Sep-28-2011		Pending	United States of America	
USE OF EXPRESSION ARRAYS TO IDENTIFY GENES FROM OVARIAN CANCER CELLS THAT ARE ASSOCIATED WITH CARBOPLATIN SENSITIVITY	60/616,851	Oct-08-2004		Expired	United States of America	
USE OF EXPRESSION ARRAYS TO IDENTIFY GENES FROM OVARIAN CANCER CELLS THAT ARE ASSOCIATED WITH CARBOPLATIN SENSITIVITY AND RESISTANCE	60/722,956	Oct-04-2005		Expired	United States of America	
CHEMO-RESISTANT CELL ASSAYS	60/712,814	Sep-01-2005		Expired	United States of America	
CHEMO-SENSITIVITY ASSAYS USING TUMOR CELLS EXHIBITING PERSISTENT PHENOTYPIC CHARACTERISTICS	60/712,815	Sep-01-2005		Expired	United States of America	
CHEMO-SENSITIVITY ASSAYS USING TUMOR CELLS EXHIBITING PERSISTENT PHENOTYPIC CHARACTERISTICS	2006287175	Sep-01-2006		Pending	Australia	
CHEMO-SENSITIVITY ASSAYS USING TUMOR CELLS EXHIBITING PERSISTENT PHENOTYPIC CHARACTERISTICS	2,620,936	Sep-01-2006		Pending	Canada	
CHEMO-SENSITIVITY ASSAYS USING TUMOR CELLS EXHIBITING PERSISTENT PHENOTYPIC CHARACTERISTICS	06814138.1	Sep-01-2006		Pending	European Patent Office	
CHEMO-SENSITIVITY ASSAYS USING TUMOR CELLS EXHIBITING PERSISTENT PHENOTYPIC CHARACTERISTICS	2008-529367	Sep-01-2006		Pending	Japan	
CHEMO-SENSITIVITY ASSAYS USING TUMOR CELLS EXHIBITING PERSISTENT PHENOTYPIC CHARACTERISTICS	11/514,172	Sep-01-2006		Abandoned	United States of America	
CHEMO-SENSITIVITY ASSAYS USING TUMOR CELLS EXHIBITING PERSISTENT PHENOTYPIC CHARACTERISTICS	PCT/US2006/034469	Sep-01-2006		Expired/PCT Period Over	Patent Cooperation Treaty	
CHEMO-SENSITIVITY ASSAYS USING TUMOR CELLS EXHIBITING PERSISTENT PHENOTYPIC CHARACTERISTICS	11/785,984	Apr-23-2007	7,642,048	Registered	United States of America	Nov-17-2026

Title	Application No.	Application Date	Registration No.	Case Status	Country	Expiry Date
CHEMO-SENSITIVITY ASSAYS USING TUMOR CELLS EXHIBITING PERSISTENT PHENOTYPIC CHARACTERISTICS	12/622,022	Nov-19-2009		Pending	United States of America	
MOLECULAR METHODS OF PREDICTING CHEMOTHERAPEUTIC RESPONSE	60/684,983	May-27-2005		Expired	United States of America	
CHEMO-SENSITIVITY ASSAYS USING TUMOR CELLS EXHIBITING PERSISTENT PHENOTYPIC CHARACTERS	60/735,813	Nov-14-2005		Expired	United States of America	
METHOD FOR INCREASING PREDICTIVE ACCURACY OF CELL CULTURE BASED BIOLOGICAL AND PHARMACOLOGICAL ASSAYS	60/819,631	Jul-11-2006		Expired	United States of America	
METHOD FOR PREDICTING A PATIENT'S RESPONSE TO AN ANTI-ANGIOGENESIS AGENT	60/907,181	Mar-23-2007		Expired	United States of America	
METHOD FOR EVALUATING ANGIOGENIC POTENTIAL IN CULTURE	2,680,528	Mar-24-2008		Pending	Canada	
METHOD FOR EVALUATING ANGIOGENIC POTENTIAL IN CULTURE	08732753.2	Mar-24-2008		Pending	European Patent Office	
COMPARISON OF ANGIOGENESIS-RELATED FACTOR EXPRESSION IN PRIMARY TUMOR CULTURES UNDER NORMAL AND HYPOXIC GROWTH CONDITIONS	61/029,164	Feb-15-2008		Expired	United States of America	
METHOD FOR EVALUATING ANGIOGENIC POTENTIAL IN CULTURE	PCT/US2008/058001	Mar-24-2008		Expired/PCT Period Over	Patent Cooperation Treaty	
METHODS FOR EVALUATING ANGIOGENIC POTENTIAL IN CULTURE	12/530,541	Mar-24-2008		Pending	United States of America	
METHODS FOR SELECTING CHEMOTHERAPY AGENTS FOR CANCER PATIENTS	60/980,098	Oct-15-2007		Expired	United States of America	
METHODS FOR SELECTING ACTIVE AGENTS FOR CANCER TREATMENT	2,700,238	Oct-15-2008		Pending	Canada	
METHODS FOR SELECTING ACTIVE AGENTS FOR CANCER TREATMENT	08840503.0	Oct-15-2008		Pending	European Patent Office	
METHODS FOR SELECTING ACTIVE AGENTS FOR CANCER TREATMENT	12/252,073	Oct-15-2008		Allowed	United States of America	
METHODS FOR SELECTING CHEMOTHERAPY AGENTS FOR CANCER PATIENTS	PCT/US2008/079964	Oct-15-2008		Expired/PCT Period Over	Patent Cooperation Treaty	
METHODS OF SIMULATING CHEMOTHERAPY FOR A PATIENT	61/110,730	Nov-03-2008		Expired	United States of America	
METHODS OF SIMULATING CHEMOTHERAPY FOR A PATIENT	13/127,337	Nov-03-2009		Pending	United States of America	
METHODS OF SIMULATING CHEMOTHERAPY FOR A PATIENT	PCT/US2009/063060	Nov-03-2009		Expired/PCT Period Over	Patent Cooperation Treaty	
METHODS OF PREDICTING A PATIENT'S RESPONSE TO EGFR TYROSINE KINASE INHIBITORS	61/053,094	May-14-2008		Expired	United States of America	
METHODS FOR PREDICTING A PATIENT'S RESPONSE TO EGFR INHIBITORS	61/142,809	Jan-06-2009		Expired	United States of America	

Title	Application No.	Application Date	Registration No.	Case Status	Country	Expiry Date
METHODS FOR PREDICTING A PATIENT'S RESPONSE TO EGFR INHIBITORS	2,721,687	May-14-2009		Pending	Canada	
METHODS FOR PREDICTING A PATIENT'S RESPONSE TO EGFR INHIBITORS	09747590.9	May-14-2009		Pending	European Patent Office	
METHODS FOR PREDICTING A PATIENT'S RESPONSE TO EGFR INHIBITORS	MX/a/2010/012408	May-14-2009		Pending	Mexico	
METHODS FOR PREDICTING A PATIENT'S RESPONSE TO EGFR INHIBITORS	12/466,129	May-14-2009		Pending	United States of America	
METHODS FOR PREDICTING A PATIENT'S RESPONSE TO EGFR INHIBITORS	PCT/US2009/043973	May-14-2009		Expired/PCT Period Over	Patent Cooperation Treaty	
METHODS FOR PREDICTING A PATIENT'S RESPONSE TO EGFR INHIBITORS	12/795,286	Jun-07-2010		Pending	United States of America	
CALIBRATION DEVICE AND METHODS FOR USE WITH A LIQUID HANDLER	2,751,786	Sep-07-2011		Pending	Canada	
CALIBRATION DEVICE AND METHODS FOR USE WITH A LIQUID HANDLER	12/878,239	Sep-09-2010		Pending	United States of America	
METHODS AND SYSTEMS FOR EVALUATING THE SENSITIVITY OR RESISTANCE OF TUMOR SPECIMENS TO CHEMOTHERAPEUTIC AGENTS	61/182,445	May-29-2009		Expired	United States of America	
METHODS AND SYSTEMS FOR EVALUATING THE SENSITIVITY OR RESISTANCE OF TUMOR SPECIMENS TO CHEMOTHERAPEUTIC AGENTS	12/791,425	Jun-01-2010		Pending	United States of America	
METHODS AND SYSTEMS FOR EVALUATING THE SENSITIVITY OR RESISTANCE OF TUMOR SPECIMENS TO CHEMOTHERAPEUTIC AGENTS	PCT/US2010/036854	Jun-01-2010		Expired/PCT Period Over	Patent Cooperation Treaty	
METHODS AND MARKERS FOR PREDICTING RESPONSES TO CHEMOTHERAPY	61/187,108	Jun-15-2009		Expired	United States of America	
METHODS AND MARKERS FOR PREDICTING RESPONSES TO CHEMOTHERAPY	13/378,507	Jun-15-2010		Pending	United States of America	
METHODS AND MARKERS FOR PREDICTING RESPONSES TO CHEMOTHERAPY	PCT/US2010/038641	Jun-15-2010		Expired/PCT Period Over	Patent Cooperation Treaty	
METHODS FOR PREDICTING A CANCER PATIENT'S RESPONSE TO ANTIFOLATE CHEMOTHERAPY	61/219,129	Jun-22-2009		Expired	United States of America	
METHODS FOR PREDICTING A CANCER PATIENT'S RESPONSE TO ANTIFOLATE CHEMOTHERAPY	12/820,573	Jun-22-2010		Pending	United States of America	
METHODS FOR PREDICTING A CANCER PATIENT'S RESPONSE TO ANTIFOLATE THERAPY	PCT/US2010/039456	Jun-22-2010		Expired/PCT Period Over	Patent Cooperation Treaty	
MULTI DRUG RESISTANCE MARKERS FOR BREAST CANCER CELLS	61/265,588	Dec-01-2009		Expired	United States of America	

Title	Application No.	Application Date	Registration No.	Case Status	Country	Expiry Date
MULTI DRUG RESPONSE MARKERS FOR BREAST CANCER CELLS	61/364,446	Jul-15-2010		Expired	United States of America	
MULTI DRUG RESPONSE MARKERS FOR BREAST CANCER CELLS	12/957,604	Dec-01-2010		Pending	United States of America	
MULTI DRUG RESPONSE MARKERS FOR BREAST CANCER CELLS	PCT/US2010/058499	Dec-01-2010		Published	Patent Cooperation Treaty	
BIOLOGICAL PATHWAYS ASSOCIATED WITH CHEMOTHERAPY TREATMENT IN BREAST CANCER	61/265,589	Dec-01-2009		Expired	United States of America	
BIOLOGICAL PATHWAYS ASSOCIATED WITH CHEMOTHERAPY OUTCOME FOR BREAST CANCER	12/957,608	Dec-01-2010		Pending	United States of America	
BIOLOGICAL PATHWAYS ASSOCIATED WITH CHEMOTHERAPY TREATMENT IN BREAST CANCER	PCT/US2010/058512	Dec-01-2010		Published	Patent Cooperation Treaty	
METHODS FOR PREDICTING A CANCER PATIENT'S RESPONSE TO SUNITINIB	61/306,784	Feb-22-2010		Expired	United States of America	
METHODS FOR PREDICTING A CANCER PATIENT'S RESPONSE TO SUNITINIB	13/029,895	Feb-17-2011		Pending	United States of America	
METHODS FOR PREDICTING A CANCER PATIENT'S RESPONSE TO SUNITINIB	PCT/US2011/025281	Feb-17-2011		Pending	Patent Cooperation Treaty	
METHODS AND SYSTEMS FOR EVALUATING THE SENSITIVITY OR RESISTANCE OF TUMOR SPECIMENS TO CHEMOTHERAPEUTIC AGENTS	61/417,678	Nov-29-2010		Expired	United States of America	
METHODS AND SYSTEMS FOR EVALUATING THE SENSITIVITY OR RESISTANCE OF TUMOR SPECIMENS TO CHEMOTHERAPEUTIC AGENTS	61/469,364	Mar-30-2011		Pending	United States of America	
METHODS AND SYSTEMS FOR EVALUATING THE SENSITIVITY OR RESISTANCE OF TUMOR SPECIMENS TO CHEMOTHERAPEUTIC AGENTS	PCT/US2011/062196	Nov-28-2011		Pending	Patent Cooperation Treaty	
METHODS AND SYSTEMS FOR EVALUATING THE SENSITIVITY OR RESISTANCE OF TUMOR SPECIMENS TO CHEMOTHERAPEUTIC AGENTS	13/304,990	Nov-28-2011		Pending	United States of America	